UNSPSC 51373473: Hydrocodone/phenylephrine/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373473 Hydrocodone/phenylephrine/pyrilamine is a Commodity code that captures pharmaceutical products and controlled substances supplied to state and local healthcare and correctional facilities. Recent state and local procurement activity under this code reflects demand for parenteral products—intravenous solutions, parenteral nutrition (TPN and PPN), and controlled-substance medications—delivered to correctional healthcare systems and public health agencies on fixed schedules with strict compliance and insurance requirements. The Washington State Department of Corrections and Seminole County, Florida represent the issuing-body mix: state correctional departments and county health and emergency-response agencies soliciting these products for incarcerated individuals and community health initiatives. Bidders must hold state business licensure, pass background clearance, and maintain substantial commercial liability and professional liability insurance; correctional-facility suppliers face particularly stringent documentation requirements for IV preparation, patient monitoring, and rapid fulfillment (24-hour delivery windows for parenteral nutrition in Washington's case).

The code shows recent activity concentrated in Washington State and Florida. The Washington State Department of Corrections issued RFQ RFQQK13020 on September 8, 2026, with response due October 7, 2026, for parenteral products and services to eight correctional facilities across three regions, with DOC targeting multiple contractors (up to three per region) and an initial contract term running November 26, 2026 through June 30, 2030. Washington State encourages participation from small businesses (25% aspirational goal), minority-owned businesses (10%), women-owned businesses (6%), and veteran-owned businesses (5%), with documented Subcontractor Inclusion Plan requirements for primes. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, though this opportunity's relevance to the hydrocodone/phenylephrine/pyrilamine code itself is unclear—the IFB scope diverges from the code's nominal pharmaceutical formulation focus. The Washington DOC opportunity represents the most direct and decision-relevant match to the code's scope.